BRIEF—Positive results for vadadustat in Japan

Mitsubishi Tanabe has announced  positive topline results from two pivotal Phase III trials of MT-6548 (vadadustat) in certain people with anemia due to chronic kidney disease (CKD).

The Japanese firm, which has in-licensed the therapy from US-based Akebia Therapeutics, plans to file MT-6548 as a therapy for renal anemia in Japan this year.

The firm says it will also advance the development of the drug in other Asian countries in which it has exclusive development and sales rights.